Content about Tolterodine

November 29, 2012
FDA approves Mylan overactive bladder drug

The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

PITTSBURGH — The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

Mylan announced the approval and launch of tolterodine tartrate tablets in the 1-mg and 2-mg strengths. The drug is a generic version of Detrol, made by Pharmacia and Upjohn, now owned by Pfizer.

Used to treat overactive bladder, tolterodine tartrate tablets had sales of about $61.5 million during the 12-month period ended in September, according to IMS Health.

November 12, 2012
Reports: CVS Caremark drops 17 drugs from formulary

The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

NEW YORK — The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

The Wall Street Journal reported that CVS Caremark would stop covering 17 drugs starting on Jan. 1, 2013, after removing 30 this year. The drugs include Abbott's Androgel (testosterone gel) for low testosterone, and Pfizer's drug Detrol LA (tolterodine tartrate) for overactive bladder.

September 7, 2012
Mylan settles with Pfizer over generic bladder drug

Generic drug maker Mylan has settled a patent litigation suit with Pfizer concerning a drug for treating bladder disorders, Mylan said Friday.

PITTSBURGH — Generic drug maker Mylan has settled a patent litigation suit with Pfizer concerning a drug for treating bladder disorders, Mylan said Friday.

The Pittsburgh-based company said it settled with Pfizer over its generic version of Detrol LA (tolterodine tartrate) extended-release capsules in the 2-mg and 4-mg strengths. The drug is used to treat urge urinary incontinence, urgency and frequency.

August 3, 2012
Drug for overactive bladder effective in patients who haven't responded well to earlier therapy, study finds

A drug made by Pfizer and used to treat overactive bladder was effective in reducing leakage of urine in patients with the disorder, according to the results of a post-approval clinical study.

NEW YORK — A drug made by Pfizer and used to treat overactive bladder was effective in reducing leakage of urine in patients with the disorder, according to the results of a post-approval clinical study.

Pfizer announced Friday results of a phase-4 study of Toviaz (fesoterodine fumarate) in the reduction of urge urinary incontinence in patients with OAB who had a less than 50% reduction in UUI when taking Detrol LA (tolterodine tartrate), a commonly prescribed treatment for the condition also made by Pfizer.

December 6, 2011
Pfizer's Toviaz safe, effective in treating overactive bladder in elderly patients

A drug made by Pfizer appears to work in treating overactive bladder in elderly patients, according to results of a clinical trial released Monday.

NEW YORK — A drug made by Pfizer appears to work in treating symptoms of overactive bladder in elderly patients, according to results of a clinical trial released Monday.

Pfizer said that results of study A0221049 of the drug Toviaz (fesoterodine fumarate) worked better than placebo in reducing the number of urgency urinary incontinence episodes. The 12-week study enrolled 562 elderly people in the United States. The drug already has Food and Drug Administration approval for treating overactive bladder.